Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma

Semlitsch T, Zengerer A, Jeitler K

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Semlitsch T, Zengerer A, Jeitler K. Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma. Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology 42. 2013

Final publication URL
http://eprints.hta.lbg.ac.at/1015

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Melanoma; Neoplasm Metastasis; Imidazoles; Oximes

Language Published
English

Country of organisation
Austria

English summary
An English language summary is available.

Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99

AccessionNumber
32013000931

Date abstract record published
12/12/2013